Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

SEC Filing · 15-12G

Masimo Corporation

SEC Filing

Filed Jun 22, 2026Accepted Jun 22, 2026, 4:57 PM EDTCIK 937556Accession 0001104659-26-076448
Share

Company context

Masimo (Nasdaq: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve life, improve patient outcomes, reduce the cost of care, and take noninvasive monitoring to new sites and applications. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown to outperform other pulse oximetry technologies in over 100 independent and objective studies, which can be found at www.masimo.com/evidence/featured-studies/feature. Masimo SET® is estimated to be used on more than 200 million patients around the world each year and is the primary pulse oximetry at all 10 top U.S. hospitals as ranked in the 2025 Newsweek World’s Best Hospitals listing. Additional information about Masimo and its products may be found at www.masimo.com.

Historical securities (1)

Recent company filings

  1. SCHEDULE 13G/A filingAug 14, 2026
  2. 4 filingJun 12, 2026
  3. 4 filingJun 12, 2026
  4. 4 filingJun 12, 2026
  5. 4 filingJun 12, 2026

As-filed source

Primary evidence